Stocks of Biora Therapeutics Inc. (BIOR) are poised to climb above their peers

Biora Therapeutics Inc. (NASDAQ: BIOR) stock jumped 4.22% on Monday to $4.20 against a previous-day closing price of $4.03. With 1.08 million shares changed hands, the volume of the stock remained lighter than its average volume of 2.19 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $4.4800 whereas the lowest price it dropped to was $3.9300. The 52-week range on BIOR shows that it touched its highest point at $52.75 and its lowest point at $1.95 during that stretch. It currently has a 1-year price target of $82.50.

Top 5 Undervalued Stocks To Own In 2023

Microchip Maker Releases "World's Most Powerful Data Center CPU". It could allow the company who manufactures it to lead the industry as the global microchip shortage continues into the coming year. We've put together a free research report that explains all the details. Not only will you find out why analysts believe this chip manufacturer could lead the pack, you will also discover four more potential winners for the coming year.

Click here to download your Free Research Report…

Sponsored

Price Performance and Earnings:

Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of BIOR was down-trending over the past week, with a drop of -1.64%, but this was up by 8.95% over a month. Three-month performance dropped to -60.93% while six-month performance fell -76.44%. The stock lost -87.37% in the past year, while it has gained 27.56% so far this year. A look at the trailing 12-month EPS for BIOR yields -17.18 with Next year EPS estimates of -7.15. For the next quarter, that number is -1.45. This implies an EPS growth rate of 51.50% for this year and -72.70% for next year.

Float and Shares Shorts:

At present, 8.93 million BIOR shares are outstanding with a float of 8.32 million shares on hand for trading. On Oct 13, 2022, short shares totaled 14.21 million, which was 7.62% higher than short shares on Sep 14, 2022. In addition to Mr. Aditya P. Mohanty as the firm’s CEO & Director, Mr. Eric d’Esparbes serves as its Chief Financial Officer.


Institutional Ownership:

Through their ownership of 28.44% of BIOR’s outstanding shares, institutional investors have minority control over the company. Other institutions hold 0.00% of BIOR, in contrast to — held by mutual funds. Shares owned by individuals account for –. As the largest shareholder in BIOR with 22.25% of the stake, Athyrium Capital Management LP holds 42,362,097 shares worth 42,362,097. A second-largest stockholder of BIOR, Neuberger Berman Investment Advis, holds 6,541,060 shares, controlling over 3.44% of the firm’s shares. The Vanguard Group, Inc. is the third largest shareholder in BIOR, holding 5,852,581 shares or 3.07% stake. With a 0.00% stake in BIOR, the BMO MSCI Genomic Innovation Index is the largest stakeholder. A total of 38 shares are owned by the mutual fund manager.

Analysts Ratings:

Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for BIOR since 2 analysts follow the stock currently. There are 2 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 0 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With BIOR analysts setting a high price target of $100.00 and a low target of $65.00, the average target price over the next 12 months is $82.50. Based on these targets, BIOR could surge 2280.95% to reach the target high and rise by 1447.62% to reach the target low. Reaching the average price target will result in a growth of 1864.29% from current levels.


EPS: Estimates vs Actual

It is also common to use earnings estimates to evaluate a firm’s growth potential and to determine trading strategy. BIOR will report FY 2022 earnings on 03/26/2024. Analysts have provided yearly estimates in a range of -$4.14 being high and -$6.67 being low. For BIOR, this leads to a yearly average estimate of -$5.41. The earnings surprise of a firm occurs when the actual results change from the consensus earnings estimate. Biora Therapeutics Inc. surprised analysts by $1.13 when it reported -$0.75 EPS against a consensus estimate of -$1.88. The surprise factor in the prior quarter was $2.21. Based on analyst estimates, the high estimate for the next quarter is -$0.89 and the low estimate is -$1.88. The average estimate for the next quarter is thus -$1.38.

Summary of Insider Activity:

Insiders traded BIOR stock several times over the past three months with 1 Buys and 3 Sells. In these transactions, 12,506,250 shares were bought while 184,794 shares were sold. The number of buy transactions has increased to 11 while that of sell transactions has risen to 11 over the past year. The total number of shares bought during that period was 15,498,424 while 225,132 shares were sold.

Leave a Comment

Your email address will not be published. Required fields are marked *